Iron Deficiency Anemia Treatments

Find Iron Deficiency Anemia Treatments

Brand Name

Injectafer

Generic Name

Carboxymaltose

View Brand Information

FDA approval date: August 12, 2013

Classification: Parenteral Iron Replacement

Form: Injection

What is Injectafer (Carboxymaltose)?

Injectafer is indicated for the treatment of: iron deficiency anemia in: adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. adult patients who have non-dialysis dependent chronic kidney disease., iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. Injectafer is an iron replacement product indicated for the treatment of:, iron deficiency anemia in: adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. adult patients who have non-dialysis dependent chronic kidney disease. , iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum Depression: a Multicentric Randomized Open-labelled Controlled Trial

Enrollment Status: Recruiting

Publish Date: June 02, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: The objectif of the IRON-DEP Study is to assess the efficacy of intravenous (IV) versus oral iron treatment on the prevalence of postpartum depression (PPD) in women with moderate iron deficiency anemia after caesarean delivery.

A Randomized, Open-label, Two-treatment, Two-period, Two-cross-over Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants Under Fasting Conditions

Enrollment Status: Recruiting

Publish Date: May 26, 2026

Intervention Type: Drug

Study Phase: Phase 1

Summary: The goal of this clinical trial is to compare the pharmacokinetic profile of the developed drug product and reference product in healthy participants under fasting condition. The main questions it aims to answer are: * \[Question 1\] Is there significant difference in the pharmacokinetic profile between the ferric carboxymaltose injection 750 mg iron/15 mL provided by Sichuan Huiyu Pharmaceutical ...

Randomized Controlled Trial of Intravenous Ferric Carboxymaltose for Iron-Deficiency Anemia in Patients With Advanced Gastric Cancer Receiving Palliative Chemotherapy

Who is this study for: Patients with Advanced Gastric Carcinoma

Enrollment Status: Recruiting

Publish Date: April 03, 2026

Intervention Type: Other, Drug

Study Drug: Ferinject

Study Phase: Phase 3

Summary: The main objective of this study is to evaluate the efficacy and safety of IV FCM(ferric carboxymaltose) in patients with AGC receiving palliative chemotherapy. This study will also evaluate the effect of IV FCM on the treatment outcomes of palliative chemotherapy in patients with gastric cancer receiving fluoropyrimidine and platinum-based regimen in the same 1st-line palliative setting.

View All Clinical Trials

Related Latest Advances

Multidisciplinary approach to implementing ferric carboxymaltose for IV iron replacement in heart failure with iron deficiency.

Journal: Future cardiology

Published: June 03, 2026

Recurrent Severe Hypophosphatemia Following Intravenous Ferric Carboxymaltose Infusion: A Case Report.

Journal: Cureus

Published: May 11, 2026

Efficacy, Safety, and Hematologic Recovery Following Intravenous Ferric Carboxymaltose in Patients with Iron Malabsorption-Related Iron Deficiency Anemia: A Prospective Clinical Study.

Journal: Nutrients

Published: May 11, 2026

View All Latest Advances